Donanemab: FDA experts recommend approval of Alzheimer ' s drug

被引：7
|
作者：
Dyer, Owen
机构：
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2024年 / 385卷
关键词：
D O I：
10.1136/bmj.q1327
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] THE FDA NEW DRUG APPROVAL PROCESS
    GIFFORD, RW
    CONNECTICUT MEDICINE, 1980, 44 (05) : 309 - 311
  • [42] FDA drug approval summaries: Fulvestrant
    Bross, PF
    Cohen, MH
    Williams, GA
    Pazdur, R
    ONCOLOGIST, 2002, 7 (06): : 477 - 480
  • [43] Overview of FDA Drug Approval and Labeling
    Clarridge, Katherine E.
    Chin, Stacy J.
    Stone, Kelly D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (12): : 3051 - 3056
  • [44] FDA to slash drug approval times
    不详
    CHEMISTRY & INDUSTRY, 2003, (13) : 5 - 5
  • [45] FDA accelerates drug approval system
    Scott, A
    CHEMICAL WEEK, 2004, 166 (32) : 42 - 42
  • [46] US drug approval ignores science's subtleties, experts say
    Waltz, E
    NATURE MEDICINE, 2006, 12 (04) : 373 - 373
  • [47] US drug approval ignores science's subtleties, experts say
    Emily Waltz
    Nature Medicine, 2006, 12 : 373 - 373
  • [48] Drug development - Merck's Maxalt wins US FDA approval
    不详
    EUROPEAN CHEMICAL NEWS, 1998, 69 (1821): : 20 - 20
  • [49] New drugs for Alzheimer's disease: Aducanumab or Donanemab?
    Joodaki, Mehran
    Shirazi, Mona Merati
    Hosseini, Nasrin
    PHYSIOLOGY AND PHARMACOLOGY, 2024, 28 (03): : 219 - 236
  • [50] Still grasping at straws: donanemab in Alzheimer's disease
    Doggrell, Sheila A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (08) : 797 - 801
12345